SCHEMBL17375896

SCHEMBL17375896

CC(=O)NCCc1cn(Cc2ccccc2)c(C=O)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.47
MTNR1A P48039 5/20 0.46
MTNR1B P49286 5/20 0.46
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
BRD4 O60885 3/20 0.43
HPGD P15428 2/20 0.42
TSHR P16473 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 1/20 0.42
EGLN1 Q9GZT9 2/20 0.40
MAPT P10636 1/20 0.40
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17375898 0.87 GFER (0.45) GFERMTNR1AMTNR1BPOLBL3MBTL1
SCHEMBL17383385 0.87 GFER (0.45) GFERMTNR1AMTNR1BPOLBL3MBTL1
SCHEMBL17375899 0.87 GFER (0.45) GFERMTNR1AMTNR1BPOLBL3MBTL1
SCHEMBL2053376 0.72 BRD4 (0.56) BRD4HPGDSMN1; SMN2ALDH1A1NPC1
SCHEMBL16136314 0.70 HSP90AA1 (0.54) GFERPOLBL3MBTL1HPGDEGLN1
SCHEMBL7858 0.69 KDM4E (0.69) MTNR1AMTNR1BHPGDTSHRKMT2A
SCHEMBL17375925 0.69 MAPT (0.47) L3MBTL1BRD4KMT2AMEN1SMN1; SMN2
SCHEMBL17375911 0.68 MAPT (0.47) L3MBTL1KMT2AMEN1SMN1; SMN2MAPT
Hydrochloric Acid SCHEMBL31736052 0.68 KDM4E (0.67) POLBL3MBTL1HPGDTSHRKMT2A
SCHEMBL17273863 0.67 HSD17B10 (0.67) POLBHPGDSMN1; SMN2ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170198006-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-13 US disclosed
US-20170198006-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-13 US disclosed
US-20170198006-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-13 US disclosed
EP-3160477-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-05-03 EP disclosed
WO-2015200680-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-30 WO disclosed
WO-2015200680-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170198006-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 GFER 4674/4885MTNR1A 2281/4885MTNR1B 1871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.